Literature DB >> 27066162

RNA-binding Protein, GADD45-alpha, p27Kip1, p53 and Genotoxic Stress Response in Relation to Chemoresistance in Cancer.

M Saeed Sheikh1.   

Abstract

Genotoxic chemotherapeutics particularly cisplatin remain effective for clinical management of various malignancies including lung cancer. However, the development of chemoresistance leads to treatment failure. The mechanisms by which tumor cells acquire resistance to chemotherapy are multifaceted in nature and some remain to be fully elucidated. Recently, a potential role of RNA-binding protein hnRNPA0 in chemoresistance of p53-defective lung cancer cells was reported. Genotoxic (DNA damaging) chemotherapy was reported to activate hnRNPA0 which in turn post-transcriptionally regulated p27Kip1 and Gadd45-alpha by stabilizing their mRNAs. Regulation of p27Kip1 and Gadd45-alpha led to enforcement of G1/S and G2/M checkpoints thereby providing time for DNA repair and thus, resistance to chemotherapy. The identification of a signaling network involving the kinase MK2, hnRNPA0, p27Kip1 and Gadd45-alpha that may predict response to chemotherapy is an interesting finding. Further studies are now needed to gain additional insights as to whether this network is restricted only to a subset of tumors or more broadly relevant across multiple tumor types.

Entities:  

Keywords:  Gadd45-alpha; Lung cancer; hnRNPA0; p27Kip1, p53

Year:  2015        PMID: 27066162      PMCID: PMC4824310     

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  16 in total

1.  Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression.

Authors:  Chad A Corcoran; Xiuquan Luo; Qin He; Changying Jiang; Ying Huang; M Saeed Sheikh
Journal:  Cancer Biol Ther       Date:  2005-10-23       Impact factor: 4.742

Review 2.  Recent clinical advances in lung cancer management.

Authors:  David H Johnson; Joan H Schiller; Paul A Bunn
Journal:  J Clin Oncol       Date:  2014-02-24       Impact factor: 44.544

3.  GADD45 induction of a G2/M cell cycle checkpoint.

Authors:  X W Wang; Q Zhan; J D Coursen; M A Khan; H U Kontny; L Yu; M C Hollander; P M O'Connor; A J Fornace; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 4.  Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles.

Authors:  Arindam Chaudhury; Praveen Chander; Philip H Howe
Journal:  RNA       Date:  2010-06-28       Impact factor: 4.942

Review 5.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

6.  Identification of several human homologs of hamster DNA damage-inducible transcripts. Cloning and characterization of a novel UV-inducible cDNA that codes for a putative RNA-binding protein.

Authors:  M S Sheikh; F Carrier; M A Papathanasiou; M C Hollander; Q Zhan; K Yu; A J Fornace
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

7.  Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.

Authors:  Jeanne Netter; Jacqueline Lehmann-Che; Jerome Lambert; Anne Tallet; Nelson Lourenco; Hany Soliman; Philippe Bertheau; Benjamin Pariente; Mircea Chirica; Marc Pocard; Matthieu Allez; Hugues De The; Jean-Marc Gornet
Journal:  Bull Cancer       Date:  2015-01-20       Impact factor: 1.276

Review 8.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

9.  Isolation and characterization of a novel, low abundance hnRNP protein: A0.

Authors:  V E Myer; J A Steitz
Journal:  RNA       Date:  1995-04       Impact factor: 4.942

10.  Lung Cancer: Are we up to the Challenge?

Authors:  Luca Esposito; Daniele Conti; Ramyasri Ailavajhala; Nansie Khalil; Antonio Giordano
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

View more
  1 in total

1.  GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.

Authors:  Hsiao-Han Wang; Tsuey-Yu Chang; Wei-Chen Lin; Kuo-Chen Wei; Jyh-Wei Shin
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.